Our project focused on the development of innovative inhaled therapies for interstitial lung diseases has been selected for funding under the “Consolidamento Patrimoniale delle Startup Innovative – Piemonte FESR” call. This support will enable us to further advance our preclinical research activities and strengthen our pipeline, with the goal of accelerating the development of new therapeutic solutions for patients with unmet medical needs.
